These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38767507)

  • 21. A randomized phase II, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients.
    Li F; Yao FS; Zhu XJ; Gu WY; Wang XH; Chen B; Huang DP; Ding JH; Wu TQ; Zhu Y; Zhao Q; Tang YM; Song P; Zhou XG; An ZM; Guo X; Wang XL; Zhong L; Xie XB; Zhai YP
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2343-2355. PubMed ID: 31280348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical study of the Nrf2 pathway in colorectal cancer: Nrf2 expression is closely correlated to Keap1 in the tumor and Bach1 in the normal tissue.
    Chang LC; Fan CW; Tseng WK; Chen JR; Chein HP; Hwang CC; Hua CC
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):511-7. PubMed ID: 23455180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
    Sandecká V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Heindorfer A; Pavlíček P; Sýkora M; Jungová A; Kessler P; Wróbel M; Starostka D; Ullrychová J; Stejskal L; Štork M; Straub J; Pika T; Brožová L; Ševčíková S; Maisnar V; Hájek R
    Eur J Haematol; 2021 Oct; 107(4):466-474. PubMed ID: 34272773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
    Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
    Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Worth of Nrf2/BACH1/HO-1 Protein Expression in the Development of Breast Cancer.
    Barnes P; Agbo E; Wang J; Amoani B; Kwaku Opoku Y; Okyere P; Saahene RO
    Med Princ Pract; 2023; 32(6):369-378. PubMed ID: 37827129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circ_0081001 down-regulates miR-494-3p to enhance BACH1 expression and promotes osteosarcoma progression.
    Liu S; Duan K; Zhang X; Cao X; Wang X; Meng F; Liu H; Xu B; Wang X
    Aging (Albany NY); 2021 Jun; 13(13):17274-17284. PubMed ID: 34191748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bach1 regulates osteoclastogenesis in a mouse model via both heme oxygenase 1-dependent and heme oxygenase 1-independent pathways.
    Hama M; Kirino Y; Takeno M; Takase K; Miyazaki T; Yoshimi R; Ueda A; Itoh-Nakadai A; Muto A; Igarashi K; Ishigatsubo Y
    Arthritis Rheum; 2012 May; 64(5):1518-28. PubMed ID: 22127667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
    Terpos E; Katodritou E; Tsiftsakis E; Kastritis E; Christoulas D; Pouli A; Michalis E; Verrou E; Anargyrou K; Tsionos K; Dimopoulos MA; Zervas K;
    Haematologica; 2009 Mar; 94(3):372-9. PubMed ID: 19252175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of clinical and prognostic characteristics of newly diagnosed multiple myeloma with myelofibrosis patients].
    Zhang L; Li YL; Liu YM; Liu YB; Shang BJ; Cheng W; Dong XY; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(1):57-62. PubMed ID: 38178769
    [No Abstract]   [Full Text] [Related]  

  • 30. Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b.
    Fu Y; Liu X; Zhang F; Jiang S; Liu J; Luo Y
    Cell Death Dis; 2019 Apr; 10(4):319. PubMed ID: 30967527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
    Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
    Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma.
    Perroud C; Thurian D; Andres M; Künzi A; Wiedemann G; Zeerleder S; Bacher U; Pabst T; Banz Y; Porret N; Rebmann E
    Hematol Oncol; 2023 Dec; 41(5):912-921. PubMed ID: 37452600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 34. Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance.
    Cohen YC; Joffe E; Benyamini N; Dimopoulos MA; Terpos E; Trestman S; Held-Kuznetsov V; Avivi I; Kastritis E
    Leuk Lymphoma; 2016; 57(6):1382-8. PubMed ID: 26727104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
    Terpos E; Migkou M; Christoulas D; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Iakovaki M; Panagiotidis I; Ziogas DC; Fotiou D; Kastritis E; Dimopoulos MA
    Blood Cancer J; 2016 May; 6(5):e428. PubMed ID: 27232930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
    Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
    [No Abstract]   [Full Text] [Related]  

  • 37. BACH1 Promotes Pancreatic Cancer Metastasis by Repressing Epithelial Genes and Enhancing Epithelial-Mesenchymal Transition.
    Sato M; Matsumoto M; Saiki Y; Alam M; Nishizawa H; Rokugo M; Brydun A; Yamada S; Kaneko MK; Funayama R; Ito M; Kato Y; Nakayama K; Unno M; Igarashi K
    Cancer Res; 2020 Mar; 80(6):1279-1292. PubMed ID: 31919242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era.
    Wei M; Guo H; Liu S; Xu F; Zhang Y; Shi J; Xu Z; Chen Y
    Medicine (Baltimore); 2021 Oct; 100(41):e27521. PubMed ID: 34731142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.
    Huang X; Zheng J; Li J; Che X; Tan W; Tan W; Shao M; Cheng X; Du Z; Zhao Y; Wang C; Wu C; Lin D
    Theranostics; 2018; 8(12):3366-3379. PubMed ID: 29930735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.